Navigation Links
Four Pharmaceutical Companies Pay $124 Million for Submission of False Claims to Medicaid
Date:10/19/2009

WASHINGTON, Oct. 19 /PRNewswire-USNewswire/ -- Mylan Pharmaceuticals, UDL Laboratories, AstraZeneca Pharmaceuticals and Ortho McNeil Pharmaceutical have entered into settlement agreements for a total of $124 million to resolve claims that they violated the False Claims Act by failing to pay appropriate rebates to state Medicaid programs for drugs paid for by those programs, the Justice Department announced today.

The Medicaid Prescription Drug Rebate Program was enacted by Congress in 1990 out of concern for the costs that Medicaid was paying for outpatient drugs. By agreeing to participate in the Medicaid Rebate Program and signing these rebate agreements, the four companies agreed to pay quarterly rebates to Medicaid that were based upon the amount of money that health care program paid for each company's drugs. The precise amount of a rebate is determined in part by whether a drug is considered an "innovator" drug or a "non-innovator" drug. The rebate that must be paid for innovator drugs is higher than the rebate for non-innovator drugs.

Each of the companies agreed to pay a settlement to resolve allegations that it had sold innovator drugs that were manufactured by other companies and had classified those drugs as non-innovator drugs for Medicaid rebate purposes. As a result of the improper classification of these drugs, the companies underpaid their rebate obligations under the Medicaid Rebate Program.

Mylan and UDL agreed to pay $118 million to resolve allegations that they underpaid their rebate obligations with respect to several Mylan drugs (nifedipine extended release tablets, flecainide acetate, selegiline HCL, Orphenadrine Citrate Aspirin and Caffeine tablets, Triamterene/Hydrochlorothiazide, Propoxyphene HCL, Propoxyphene HCL/Aspirin/Caffeine, Prophyxphene Napsylate/Acetaminophen, Ibuprofen tablets, Bumetanide, Cephalexin and Cefactor) and several UDL drugs (nifedipine extended release tablets, selegiline HC
'/>"/>

SOURCE U.S. Department of Justice
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... 16 Today, Avantium announced the,appointment ... of its pharmaceutical,business. Gunnar Staaf previously worked ... Lilly & Company, in a range of ... important step in Avantium,s plan to,spin-out its ... a,stand-alone pharmaceutical company based on its offering ...
(Date:12/16/2009)... -- Vivakor, Inc. (OTC Bulletin Board: VIVK) ... Baker Consulting out of Walnut Creek, California ... out of South Florida. Baker Consulting ... with business development, financing and assisting the ... Specifically, Baker Consulting is exploring potential acquisition ...
(Date:12/16/2009)... Ill., Dec. 16 Naurex Inc., a ... depression and other CNS disorders based on its ... data presented at a major medical meeting showed ... and anxiolytic-like activity with no signs of the ... the NMDA receptor(1). The studies also showed ...
Breaking Medicine Technology:Avantium Appoints Gunnar Staaf as CEO Pharma 2Vivakor Signs Business Development Agreement With Baker Consulting 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 3Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 5Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 6Cardinal Health Names Patricia Morrison Chief Information Officer 52643 1Cardinal Health Names Patricia Morrison Chief Information Officer 52643 2Dialysis Corporation of America Announces Second Quarter 2009 Earnings Release Date 52640 1Dialysis Corporation of America Announces Second Quarter 2009 Earnings Release Date 52640 2Are Patients Becoming Victims in Hospital Overcrowding Turf Wars 3F Experts Ask 52637 1Are Patients Becoming Victims in Hospital Overcrowding Turf Wars 3F Experts Ask 52637 2
(Date:12/16/2009)... NORCROSS, Ga., Dec. 16 Immucor, Inc. (Nasdaq: ... instrument-reagent systems to the blood transfusion industry, today announced ... its board as a new independent director, effective January ... in blood banking and transfusion medicine for more than ... and Medicine at the University of Virginia School of ...
(Date:12/16/2009)... most widely used human embryonic stem cell lines lack ... that must be addressed to ensure that all sectors ... a University of Michigan research team. ,, In the ... analyzed 47 embryonic stem cell lines, including most of ... scientists determined the genetic ancestry of each line and ...
(Date:12/16/2009)... seven that increase susceptibility to disease , , WEDNESDAY, ... with increased susceptibility to leprosy have been identified ... researchers, who analyzed more than 10,000 DNA samples ... said their discovery highlights the important role that ... of leprosy. , "Though leprosy is not common, ...
(Date:12/16/2009)... at work on a malaria elimination study in Africa ... the disease using cell phone records. , The scientists ... often residents of Zanzibar travel and where they go. ... coast of Tanzania in East Africa, Zanzibar has drastically ... study as part of deliberations on whether to launch ...
(Date:12/16/2009)... they cut bleeding time in half, but use in humans ... -- Hoping to improve on nature, researchers have built and ... be used in trauma or other cases where blood just ... with material that is used in degradable stitches, which dissolve ... biomedical engineering at Case Western Reserve University, and lead author ...
Breaking Medicine News(10 mins):Health News:Immucor Appoints New Board Director 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 3Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 4Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 5Health News:Leprosy Genes Identified 2Health News:Scientists use cell phone records to predict spread of malaria 2Health News:Scientists use cell phone records to predict spread of malaria 3Health News:Synthetic Platelets Put the Brakes on Blood Loss 2Health News:Synthetic Platelets Put the Brakes on Blood Loss 3
... May 15 (Nasdaq: WHRT, TSX:,WHT) World Heart ... 2008, it had received a NASDAQ Staff Determination ... on The NASDAQ Capital Market,has been denied. The ... a,definitive plan evidencing its ability to achieve near ...
... 15 The US-China Business,Council (USCBC) today encouraged ... way in China in response to the devastating ... USCBC member companies have already pledged several million ... aid to earthquake victims and many,have established matching ...
... a press release earlier this,year, the FDA issued a ... (OTC) cough and cold products should not,be used to ... age because,serious and potentially life-threatening side effects can occur ... and caregivers that OTC cough,and cold medicines not be ...
... in preliminary trial , , THURSDAY, May 15 (HealthDay ... a lower risk of the heart rhythm abnormality ... coronary disease. , "Our finding alone doesn,t prove ... supports the hypothesis that they may," said study ...
... on relationship marketing, SAN DIEGO, May 15 ... consumers to "Live Life to the Youngest" and,pursue ... younger, received,a Silver Award at the 2008 Pharmaceutical ... May 1, 2008. The,RealAge/ARD Marketing Valtrex(R) campaign was ...
... & 15 at Paris Las ... ... musical journey across America when Las Vegas-based HIV/AIDS,charity Golden Rainbow presents its ... 14 and 15 in Le,Theatre des Arts at Paris Las Vegas., ...
Other Medicine News:Health News:WorldHeart Announces Possible Delisting Action by NASDAQ 2Health News:WorldHeart Announces Possible Delisting Action by NASDAQ 3Health News:US Companies Aid Chinese Earthquake Victims 2Health News:US Companies Aid Chinese Earthquake Victims 3Health News:US Companies Aid Chinese Earthquake Victims 4Health News:US Companies Aid Chinese Earthquake Victims 5Health News:US Companies Aid Chinese Earthquake Victims 6Health News:US Companies Aid Chinese Earthquake Victims 7Health News:Saline is Safe Alternative to Harmful Cough and Cold Products 2Health News:Statins May Help Older Women Control Irregular Heartbeat 2Health News:RealAge Wins Silver PhAME Award 2Health News:Golden Rainbow Takes a Musical Journey for Its 22nd Annual 'Ribbon of Life' Production Show 2
... Microtome is ideal for sectioning of specimens in ... Specimen rise is automatic and accurate with section ... increments of 2 microns. Will accommodate MNL ... Vibratomes Freezing Stages , ...
... The Starter Package is a ... your laboratory. The package includes ... kit, additional mounting blocks, v-block ... and a rotating stage assembly ...
... Professional Package is the best ... laboratory. The package includes the ... additional mounting blocks, v-block adapter, ... a sapphire blade for the ...
... System provides a versatile means of sectioning ... The 1000 employs a vibrating blade ... embedding. The creation of artifacts, the ... activities, and other deleterious effects inherent in ...
Medicine Products: